Drugs / Ad4-EnvCN54
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03408262 | Oct 2017 → Feb 2020 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad4-EnvCN54 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03408262 ↗ |
| Route | Oral | “oral Adenovirus serotype 4 vector prime expressing HIV-1 CN54 envelope” NCT03408262 ↗ |